Locally Advanced Non Small Cell Lung Cancer
Conditions
Keywords
beclomethasone propionate, radiation pneumonitis, NSCLC, radical radiotherapy, Preventive effect
Brief summary
Radical radiotherapy is the main treatment of locally advanced lung cancer, and radiation pneumonia is the main toxic effects of radiotherapy. Among them, the fatality rate of severe radiation pneumonia can reach 50%, which is very harmful to tumor patients. At present, the treatment mode of radiation pneumonia is very few, and the therapeutic effect is poor. The prevention of radiation pneumonitis may be the best way to reduce the number of patients with Post-radiotherapy pneumonia. Previous small clinical studies have shown that the incidence of radiation pneumonia in inhaled beclomethasone group (2 /28) was significantly lower than that in oral prednisone group (8 /29) during radiotherapy. The purpose of this study was to compare the efficacy and safety of radiotherapy between the therapeutic group (inhaled beclomethasone during radiotherapy) and the control radiotherapy group (patients received radiotherapy only), especially the incidence of radiation-induced pneumonia within half a year.
Detailed description
To compare the incidence of radiation pneumonia, effect and side effects of radiotherapy in lung between beclomethasone inhalation therapeutic group and control radiotherapy group in patients with locally advanced non-small cell lung cancer (NSCLC) during radiotherapy.
Interventions
DRUGBeclomethasone propionate
Beclomethasone propionate inhaled twice daily during radiotherapy
Sponsors
Shanghai Pulmonary Hospital, Shanghai, China
Tongji University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. The subjects understood the requirements and risks of the study fully and signed the informed consent form. 2. Aged between 18 and 70 years; 3. Histologically or cytologically confirmed diagnosis of locally advanced non-small cell lung cancer. 4. All of these patients have pointers to radical radiation and can't be treated surgically. 5. ECOG PS of 0-2; 6. Women of childbearing age had negative pregnancy tests and were willing to accept drugs or intrauterine contraception, while men of childbearing age were willing to accept contraception voluntarily. 7. Adequate hematologic function: Peripheral blood neutrophil count \> 2000 cells / uL, Platelet count \> 100\*109 / L; Hemoglobin \>9.0g/dL; 8. Blood total bilirubin \< 2 times normal upper limit, blood AST and ALT ≤ 2. 5 times normal upper line; 9. Inosine clearance ≥ 60ml / min; 10. Life expectancy of at least 12weeks.
Exclusion criteria
1. With severe or uncontrolled systemic diseases; 2. With a history of asthma, systemic immune diseases, such as the need for long-term hormone treatment in patients; 3. The lung function decreased obviously; 4. Those receiving targeted therapy or biological therapy at the same time; 5. Allergic to beclomethasone propionate; 6. Pregnant or lactating women; 7. Accompanied by uncontrolled diabetes, need to take oral hormone treatment of sarcoidosis and vasculitis, lupus erythematosus and other immune diseases; 8. In recent 5 years has suffered from other tumors: cervical cancer, basal cell carcinoma of the skin, and so on; 9. The estimated survival time was less than 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of radiation pneumonia between two groups of patients | Chest CT assessment every 6 weeks since thoracic irradiation, up to 36 weeks. | To evaluate the incidence of radiation pneumonia in 36weeks since thoracic irradiation between two groups of patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate between two groups of patients | tumor assessment every 6 weeks since thoracic irradiation , up to 36 weeks. | To evaluate Objective response rate every 6weeks since thoracic irradiation. |
| Side effects between two groups of patients | 36 weeks . | To evaluated in the 36 weeks since the thoracic irradiation began according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Quality of life between two groups of patients | 36 weeks | evaluated every 6 weeks since the thoracic irradiation began according to the EORTC Quality-of-Life Questionnarire-Lung Cancer 13 Module(EORTC OLO-LC13) |
Countries
China
Contacts
Primary Contactcaicun zhou, phD MD
Backup Contactjie zhang, MD
Outcome results
None listed